The Neuroprotection of Kappa Opioid Receptor Agonist BRL52537 is Partly Through Enhancing Endogenous GABA Function  by Chen, Tsung-Ying et al.
available at http://ajws.elsevier.com/tcmj
Tzu Chi Medical Journal
 TZU CHI MED J  December 2008  Vol 20  No 4
*Corresponding author. Department of Anesthesiology, Buddhist Tzu Chi General Hospital, 
707, Section 3, Chung-Yang Road, Hualien, Taiwan.
E-mail address: mhshyr@tzuchi.com.tw
© 2008 Buddhist Compassion Relief Tzu Chi Foundation
Original Article
The Neuroprotection of Kappa Opioid Receptor 
Agonist BRL52537 is Partly Through Enhancing 
Endogenous GABA Function
Tsung-Ying Chen1,2, Hsu-Tang Liu1, Chia-Ling Lee1, Jimmy Ong1, 
E-Jian Lee3, Ming-Hwang Shyr1*
1Department of Anesthesiology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan
2Graduate Institute of Clinical Medicine, Department of Nursing, Tzu Chi University, Hualien, Taiwan
3Neurophysiology Laboratory, National Cheng Kung University and Department of Surgery, National Cheng Kung University 
Hospital, Tainan, Taiwan
Abstract
Objective: We previously demonstrated that pretreatment with selec-
tive κ-opioid agonist BRL52537 hydrochloride [(κ)-1-(3,4-dichlorophenyl) 
acetyl-2-(1-pyrrolidinyl) methylpiperidine] provides ischemic neuroprotec-
tion following transient focal ischemia in rats. The present study was under-
taken to determine whether the neuroprotection of BRL52537 attenuates 
ischemia-evoked efflux of GABA in the striatum in vivo following transient 
focal ischemia.
Materials and Methods: Using the intraluminal filament technique, 
halothane-anesthetized male Wistar rats (n = 20) were subjected to 2 hours 
of middle cerebral artery occlusion (MCAO). In a blinded, randomized fash-
ion, rats were treated with saline (vehicle) or 1 mg/kg/hr BRL52537 started 
30 minutes before MCAO and continued at 0.5 mL/hr until the 22nd hour 
of reperfusion. We also utilized in vivo microdialysis to measure extracel-
lular levels of amino acids including glutamate and GABA in the striatum 
during the 2 hours of MCAO and 3 hours of reperfusion. Data are presented 
as mean ± standard error of the mean. Statistical analysis was performed 
using the unpaired Student’s t test.
Results: Infarct volume of 26.2 ± 3.6% in the cortex and 42.9 ± 4.2% in 
the striatum were significantly attenuated in the BRL52537 group when 
compared with the control subjects (42.8 ± 5.7% in cortex; 74.0 ± 3.7% in 
striatum). Pretreatment with BRL52537 significantly increased microdia-
lysate levels of GABA in the striatum during MCAO and early reperfusion, 
when compared with the control subjects. However, other amino acids did 
not show significant changes.
Conclusion: The data demonstrated that BRL52537 provided robust 
ischemic neuroprotection with altering ischemia-evoked efflux of GABA 
in the striatum during ischemia and early reperfusion. [Tzu Chi Med J 
2008;20(4):280–285]
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1. Introduction
The opioidergic system in the brain has been impli-
cated in the pathophysiology of cerebral ischemia 
[1–4]. Opioid receptors in the central nervous system 
have been divided into various subtypes, including 
mu (μ), kappa (κ) and delta (σ). In addition to playing a 
role in antinociception, several experimental studies 
have demonstrated that kappa opioid receptor (KOR) 
agonists attenuate histological brain injury [5–7] as 
well as improve functional recovery in animal mod-
els of global and focal cerebral ischemia [8,9].
Excessive activation of excitatory amino acid recep-
tors is widely accepted as being integral to the patho-
genesis of brain damage following ischemia. There is 
a marked elevation in the extracellular concentrations 
of glutamate in the neocortex [10–13] and striatum 
[10,14] during cerebral ischemia, which correlates with 
the resultant degree of ischemic brain damage [10,13]. 
However, it has been argued that glutamate in the 
extracellular fluid may be a consequence rather than 
a cause of progressive neuronal injury [15]. Of the 
neurotransmitters, glutamate has been studied the 
most often in relation to the development of cerebral 
ischemia-induced cell death. While many neurotrans-
mitter systems play roles in ischemia-induced neuro-
nal death, the γ-aminobutyric acid (GABA)-ergic system 
may be of particular importance because it functions 
in opposition to that of glutamate. Compared with glu-
ta mate, GABA has received relatively little attention 
in the area of cerebral ischemia-induced neuronal 
death and it may be an attractive pathway for neuro-
protection after cerebral ischemia.
There is good evidence that GABA exerts an in-
hibitory tone on glutamate mediated neuronal activity 
[16] and several different approaches have revealed 
that enhanced GABA function can inhibit N-methyl-D-
aspartic acid (NMDA) receptor-mediated response 
[17–19]. Thus, enhancing GABAergic inhibitory mech-
anisms in vivo might also be expected to attenuate 
the excitotoxic process and provide neuroprotection.
We previously demonstrated that the selective 
KOR agonist, BRL52537 hydrochloride ((±)-1-(3,4-
dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperi-
dine), pro vides significant neuroprotection when given 
as a pretreatment as well as when started at the onset 
of reperfusion in the rat model of middle cerebral 
artery occlusion (MCAO) [20]. We also demonstrated 
that BRL52537 provides a long therapeutic opportu-
nity (at least 6 hours) for ischemic neuroprotection 
without altering ischemia-evoked efflux of dopamine 
and its metabolites in the striatum during ischemia and 
early reperfusion [21]. However, the signaling mech-
anisms utilized by KOR under normal conditions or 
during neuroprotective actions are not well estab-
lished in vivo. Therefore, we sought to use in vivo 
microdialysis to test the hypothesis that BRL52537 
provides neuroprotection by limiting excessive gluta-
mate release while preserving an adequate amount 
necessary for neurotrophic and neurotransmitter func-
tion or the GABA neurotransmission system.
2. Materials and methods
2.1. Animal preparation
The experimental protocols were approved by the Tzu 
Chi General Hospital Animal Care and Use Committee. 
All techniques were as previously described. Briefly, 
adult male Wistar rats (250–300 g) that had fasted from 
food overnight were anesthetized with halothane 1.0–
2.0% for 3–5 minutes in oxygen-enriched air (inspira-
tory oxygen concentration, 25–30%) and spontaneous 
breathing was allowed. Using aseptic surgical tech-
niques, the right femoral artery was cannulated with 
PE50 tubing to monitor arterial blood pressure and 
sample arterial blood gases; meanwhile, the femoral 
vein was cannulated and tunneled subcutaneously as 
well as exteriorized using a swivel for venous access 
and drug administration. Rectal temperature was main-
tained using a heat lamp throughout the surgical pro-
cedures, during MCAO and during early reperfusion.
2.2. Local cerebral blood flow monitoring
Laser Doppler flowmetry (LDF Model MBF3D; Moor 
Instruments Ltd., Devon, UK) was used for laser cere-
bral blood flow (LCBF) measurements. The scalp was 
incised along the midline, and the skull was thinned 
using a high-speed drill over the right parietal cortex; 
coordinates were 2 mm posterior and 6 mm lateral to 
the bregma for the placement of the LDF probe. To 
allow for continuous monitoring of the LDF, the head-
piece of a specially designed cradle was modified to 
allow for free rotation around the longitudinal axis of 
the rat and was equipped with a snout mask for spon-
taneous ventilation as well as a holder for the LDF 
probe. The probe was then positioned over an area 
devoid of large cortical blood vessels, and the position 
was not changed throughout the experiment. LCBF 
was serially measured at 5-minute intervals prior to, 
during cerebral ischemia and until 120 minutes after 
reperfusion to collect the microdialysates. The inci-
sion was stapled, and the animals were then returned 
to their cages. The LCBF values were calculated and 
expressed as percentages of the baseline values.
2.3. Transient focal ischemia model
Transient focal ischemia (2 hours) is produced by 
MCAO by using an intraluminal suture technique as 
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previously described [20,21], with some modifica-
tions. Briefly, the right common carotid artery was ex-
posed through a paramidline incision, and the external 
carotid artery was ligated. The occipital artery branch 
of the external carotid artery was coagulated, and the 
internal carotid artery (ICA) was separated from the 
vagus nerve. The pterygopalatine artery was ligated 
with a 4-O silk suture close to its origin. Ischemia was 
produced by advancing a 4-O monofilament nylon 
suture, with its distal tip rounded by application of heat, 
into the ICA through a puncture in the common ca-
rotid artery until the LDF signal displayed a significant 
reduction. After placement, the intraluminal suture was 
secured with a 4-O silk suture tied around the ICA. 
Reperfusion was produced by withdrawal of the intra-
luminal suture; this was associated with rapid resto-
ration of the LDF signal. Our previously reported data 
demonstrated that a reduction to < 40% of the base-
line LDF signal was critical in producing consistent 
infarction volume in our model of MCAO.
2.4. Animal grouping and assessment of 
infarction volume
We used a blinded randomized method to divide the 
rats into: Group I—saline (vehicle); and Group II—KOR 
agonist BRL52537 (1 mg·kg−1·hr−1; from Research 
Biochemical International, Natick, MA, USA). All infu-
sions start at 30 minutes before MCAO and continued 
at 0.5 mL/hr until the 22nd hour of reperfusion. Follow-
ing the closure of the operative sites, the animal was 
allowed to awaken from the anesthesia. After 22 hours 
of reperfusion, the rats were deeply anesthetized with 
5% halothane and decapitated. The brain was sliced 
into seven 2-mm thick coronal sections from the fron-
tal pole for staining with 1% triphenyltetrazolium chlo-
ride (TTC) in saline at 37°C for 30 minutes [1]. Each 
slide was drawn using a computer-based image anal-
ysis system using the OS/2 operating system (MCID, 
Imaging Research, Ontario, Canada) and the infarct 
area was numerically integrated across each section 
and over the entire ipsilateral hemisphere. Infarct vol-
umes were measured separately in the cerebral cor-
tex and caudoputamen (CP) complex and expressed 
as percentages of the ipsilateral structure volume as 
described previously [21,22].
2.5. In vivo cerebral microdialysis
We placed each rat’s head in a Kopf stereotaxic frame, 
and the microdialysis cannulas were placed into the 
striatum bilaterally. The cannula was advanced to pre-
determined coordinates of 0.5 mm anterior and 2.5 mm 
lateral to the bregma at a depth of 6 mm from the 
dura using a micromanipulator and they were fixed 
in position using dental cement [21]. Each dialysis 
probe used in the study was a microdialysis probe 
(CMA/11; CMA/Microdialysis AB., Stockholm, Sweden) 
which possessed greater spatial resolution and caused 
less tissue damage. It consisted of a cuprophane mem-
brane with an outside diameter of 0.24 mm. The outer 
steel shaft diameter was 0.38 mm. The dialysis mem-
brane diameter was 300 μm and had a molecular mass 
cut-off of 6000 Daltons. Two hollow silica perfusion 
tubes were inserted into the dialysis fiber so that the 
ends were 3 mm apart (for the striatum) and 2 mm apart 
(for the cortex). The distance between the tips con-
stituted the effective dialyzing area of the cannula. A 
2-hour postsurgical equilibration period was given be-
fore the experiment began. Microdialysis cannula was 
perfused with artificial cerebrospinal fluid at 1 μL/min. 
The in vitro recovery from the 3-mm microdialysis 
probes was 10–15%. Rats were randomized to receive 
either intravenous infusions of 1 mg/kg/hr BRL52537 
or saline (0.5 mL/hr) that were initiated 30 minutes 
prior to MCAO. Microdialysates were collected in ep-
ochs of 15 minutes from equilibration to 2 hours after 
reperfusion and stored at −80°C. The brains were har-
vested at 22 hours of reperfusion, sectioned for con-
firmation of microdialysis probe position and analysis 
of infarction volume using TTC staining.
2.6. High performance liquid 
chromatography measurements
An ESA (ESA Inc., Chelmsford, MA, USA) Coulochem 
high performance liquid chromatography pump, ESA 
electrochemical detector, and an automatic integrator 
were used with a reverse phase column. Microdialysates 
(15 μL samples) were derivated using o-phthaldehyde 
(OPA) via an ESA or Gilson (Gilson Inc., Middleton, WI, 
USA) autosampler. The mobile phase, 0.1 M Na2HPO4, 
0.13 mM Na2EDTA and 28% methanol, was continu-
ously recycled every 2 weeks and then changed with 
a fresh solution. The total area under the peaks were 
integrated and compared with the homoserine inter-
nal standard. The full chromatograms of the amino 
acid profiles were obtained. Peaks for excitotoxic and 
inhibitory amino acids including glutamate, glycine, 
taurine, alanine and GABA were well resolved.
2.7. Statistical analysis
Physiological parameters and mean LDF measurements 
between the groups were subjected to unpaired Stu-
dent’s t test. Differences in the infarct volume were 
determined using one-way ANOVA. Post hoc analy sis 
comparisons were made with the Newman-Keuls test. 
Data are presented as mean ± standard error of the 
mean. For microdialysis experiments, GABA in the 
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microdialysates between the groups were analyzed 
using unpaired Student’s t test.
3. Results
There were no physiologically relevant differences be-
tween the two groups for all the monitored variables 
such as mean arterial blood pressure, pH value, PaCO2, 
PaO2, hemoglobin level, rectal and temporalis muscle 
temperature during the pre-ischemic, ischemic and 
30 minutes post-ischemic experimental period (data 
not shown). Pericranial temperature was not signifi-
cantly different between the two groups during the 
experiment (saline 35.6 ± 0.3°C vs. BRL 36.0 ± 0.2°C). 
There were also no significant daily body weight loss 
differences at 24 hours after the procedures between 
the two groups (saline 11.0 ± 0.9% vs. BRL 13.4 ± 1.0%). 
LDF-determined cerebral perfusions were not different 
between the groups during MCAO. Similarly, LDF was 
promptly restored on withdrawal of the intraluminal 
sutures during reperfusion in both groups.
TTC-determined infarct volumes were significantly 
attenuated in both the cortex (26.2 ± 3.6%) and CP 
com plex (42.9 ± 4.2%) in the BRL group as compared 
with the control subjects (42.8 ± 5.7% in cortex; 
74.0 ± 3.7% in CP complex) (Table 1). In the microdi-
alysis experiments, in vitro probe recovery for GABA, 
prior to implantation of the probe, was 26 ± 5% (n = 8 
probes). A total of 10 animals per group were included 
in the final analysis. There was almost a time-
dependent significant increase in GABA concentra-
tion from pre-ischemic values during MCAO when we 
compared the BRL group with the saline group (p < 0.05 
at 60, 90 and 120 minutes, but p = 0.05 at 75 and 
105 minutes). These values gradually returned to pre-
ischemic baseline values at reperfusion. How ever, 
there were no differences in the variables of gluta-
mate (Fig. 1) and the other amino acids (glycine, tau-
rine, alanine) in the dialysates with MCAO between 
the rats treated with saline and BRL.
4. Discussion
The study results demonstrated the following impor-
tant findings: first, the pre-30 minute intravenous ad-
ministration of a selective KOR agonist, BRL52537, 
can provide neuroprotection as seen in previous 
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Fig. 1 — Variable values of GABA and glutamate by high performance liquid chromatography during the experiment in 
both groups. *p < 0.05 when comparing the two groups. Data presented as mean ± standard error of the mean.
Table 1 — Infarction volume between two groups*
Infarct volume  
Cerebral
 
Caudoputamen
 
Hemisphere(% of ipsilateral 
cortex
 
complex
structure)
Control group 42.8 ± 5.7 74.0 ± 3.7 24.8 ± 2.9
BRL group 26.2 ± 3.6† 42.9 ± 4.2† 15.1 ± 1.7†
*Data presented as mean ± standard error of the mean; †p < 0.05 vs. 
control group, unpaired Student’s t test.
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studies [20–22]. Secondly, BRL52537, when given as 
a pretreatment, significantly increased the GABA con-
centration in the BRL52537-treated group when com-
pared with the control group. However, there were no 
significant differences in the increases in glutamate 
during the MCAO period between the groups. The data 
demonstrated that BRL52537 may provide robust is-
che mic neuroprotection with altering ischemia-evoked 
efflux of GABA but not glutamate in the striatum dur-
ing ischemia and early reperfusion.
KOR agonists as a potential therapy for ischemic 
neuroprotection have been of interest for several years 
[5–7]. As seen in previous studies, we have shown 
that BRL52537 hydrochloride is highly specific for 
the KOR [20] and provides significant ischemic neu-
roprotection even when delayed for up to 6 hours of 
reperfusion after 2 hours of MCAO in rats [21]. In this 
BRL52537 pretreatment study, we demonstrated that 
there was neuroprotection without alterations in core 
body and pericranial temperatures as well as no sig-
nificant effects on the physiological parameters eval-
uated within this study.
We did not observe modulation of the ischemic-
evoked acute release of dopamine or its metabolites 
in our previous study [21], though some in vivo stud-
ies demonstrated that the KOR agonist modulated 
dopaminergic neurotransmission in the substantia 
nigra, neostriatum, and the mesolimbic systems 
[23–25]. Goyagi et al demonstrated that BRL52537 
attenuated ischemic-evoked nitric oxide production 
in the striatum in vivo and postulated that this may 
account for the neuroprotective effects [26], but the 
precise signaling of this interaction remains unclear. 
Therefore, several researchers support the hypothe-
sis that the antiexcitotoxic mechanism may be im-
portant in the neuroprotection provided by KOR 
agonists in cerebral ischemia [7,20–22]. It has been 
demonstrated that KOR agonist modulated gluta-
mate toxicity via inhibition of presynaptic glutamate 
release, possibly by closing N-type Ca2+ channels and 
also inhibiting excitatory postsynaptic potentials by 
attenuating presynaptic Ca2+ influx [26]. Other re-
searchers reported that the attenuation of glutamate 
was released with graded ischemia in experimental 
stroke with a KOR agonist, as well as the modulation 
of the inhibitory neurotransmitter GABA [27]. There 
is substantial evidence linking excessive glutamate 
neurotransmission to the development of neuronal 
death following ischemic events [28,29]. While many 
neurotransmitter systems play roles in ischemic neu-
ronal death, the GABAergic system may be important 
due to its functions as opposition to that of glutamate 
[29]. GABA has received relatively little attention in 
the area of ischemic neuroprotection when compared 
with glutamate. As our study showed in the BRL group, 
GABA significantly accumulated in the extracellular 
space during transient cerebral ischemia but glutamate 
did not significantly increase. In addition, both amino 
acids gradually returned to normal levels after reper-
fusion. Extracellular GABA accumulation has been 
shown using in vivo microdialysis and cortical cup 
techniques with the hippocampus, striatum and cer-
ebral cortex during global cerebral ischemia [30–34]. 
These results are compatible with our results using 
the microdialysis technique at the ischemic striatum 
to extract the GABA concentration.
GABA function may be decreased following an 
ische mic insult and then presents evidence that 
some compounds that increase GABAergic function 
are neuroprotective. Several mechanisms have been 
propos ed for the increased extracellular GABA dur-
ing ischemia [29,32]. The mechanisms include: (1) 
depolarization-induced Ca2+-dependent vesicular re-
lease; (2) depolarization-induced Ca2+-dependent re-
versal of GABA transporters; and (3) leakage of GABA 
from injured, permeable terminals. In addition to de-
polarization, other factors generated by ischemia can 
cause accumulation of extracellular GABA like ara-
chidonic acid and reactive oxygen species [29]. There 
are some questions with regard to the consequences 
of extracellular GABA accumulation. It may be that 
accumulated GABA can downregulate GABA synthe-
sis transiently [28] and also be opposite to glutamate 
function. From our study results, we believe that the 
KOR agonist, BRL52537, provided neuroprotection, 
at least partially, by accentuation of the function of 
the inhibitory neurotransmitter GABA.
In conclusion, the data demonstrated that pre-
treatment of continuous intravenous infusion of the 
potent and selective KOR agonist BRL52537 attenu-
ated brain damage in rats subjected to transient focal 
ischemia. The neuroprotection of BRL52537 is par-
tially through the enhancement of GABA function.
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